Target intelligence / Profile preview

Immunoglobulin heavy variable 2-26 (IGHV2-26)

Target
IGHV2-26
Molecular classification
Other, immunoglobulin variable gene segment, V-region gene segment of the immunoglobulin heavy chain
01

Overview

Immunoglobulin heavy variable 2-26 is a variable (V) gene segment of the immunoglobulin heavy chain locus in humans. This segment encodes part of the antibody variable domain, which is responsible for antigen recognition. IGHV2-26, like other IGHV genes, contributes to the diversity of the antibody repertoire via V(D)J recombination, allowing the immune system to recognize a vast array of antigens. The variable domain, together with the paired light chain, forms the antigen-binding site of immunoglobulins (antibodies). IGHV2-26 is not a receptor, enzyme, or traditional drug target. It is essential for immune defense, but its direct manipulation is not standard in therapeutics; it is studied primarily in immunology, repertoire analysis, or certain research contexts.

Other names
IGHV2-26Immunoglobulin heavy variable 2-26IGH V-region 2-26
02

Mechanism of action

If any antibody uses this V-gene, its mechanism would be antigen binding via the variable region.

03

Biological functions

Antigen bindingImmune responseAntibody diversity generation
04

Disease associations

Otherinfectionautoimmunityimmune system-related diseases
05

Safety considerations

No specific therapeutic safety concerns directly related to this gene segment; standard antibody therapy safety profiles apply generally.
06

Biomarkers

IGHV gene family usage can be studied as a biomarker of immune repertoire or clonality

Beyond the preview

Go deeper on Immunoglobulin heavy variable 2-26 (IGHV2-26).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy variable 2-26 (IGHV2-26).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call